DOGWOOD THERAPEUTICS INC (DWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.04+0.97%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DWTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 Dogwood Therapeutics Announces Third Quarter 2026 Financial Results - Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in N…
Stated in 3 of 3 supplied quarters. Management reported: “Research and development expenses for the third quarter of 2026 were $3.3 million, compared to $14.5 million for the third quarter of 2025.” “Net loss attributable to common stockholders for the third quarter of 2026 was $4.9 million, or $0.14 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $15.7 million, or $8.20 basic and diluted net loss per share, for the third quarter of 2025.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“ Exhibit 99.1 Dogwood Therapeutics Announces Third Quarter 2026 Financial Results - Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in N…”
“ Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 pat…”
“ Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA a…”
[/TABLE] [TABLE] • | Cash on hand of $4.9 million along with the private placement of $5 million provides operational runway through the first quarter of 2027.
Stated in 3 of 3 supplied quarters. Management reported: “Research and development expenses for the third quarter of 2026 were $3.3 million, compared to $14.5 million for the third quarter of 2025.” “Net loss attributable to common stockholders for the third quarter of 2026 was $4.9 million, or $0.14 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $15.7 million, or $8.20 basic and diluted net loss per share, for the third quarter of 2025.”
“[/TABLE] [TABLE] • | Cash on hand of $4.9 million along with the private placement of $5 million provides operational runway through the first quarter of 2027.”
“[/TABLE] Second Quarter 2026 Financial Results Research and development expenses for the second quarter of 2026 were $3.2 million, compared to $2.6 million for the second quarter of 2025.”
“• Cash on hand of $13.2 million provides operational runway into the fourth quarter of 2026.”
The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.
Stated in 3 of 3 supplied quarters. Management reported: “The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.” “Study to begin enrolling in the second-half of 2026 for the treatment of chemotherapy induced pain and peripheral neuropathy (“CIPPN”).”
“The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.”
“Study to begin enrolling in the second-half of 2026 for the treatment of chemotherapy induced pain and peripheral neuropathy (“CIPPN”).”
“Study to begin enrolling in mid-2026 for the treatment of chemotherapy-induced pain and peripheral neuropathy (“CIPPN”).”
In the third quarter of 2026, the Company received and recognized $0.1 million in licensing revenue for its first payment under the PRIDCor License Agreement and recognized cost of goods sold of $0.1…
Stated in 3 of 3 supplied quarters. Management reported: “In the third quarter of 2026, the Company received and recognized $0.1 million in licensing revenue for its first payment under the PRIDCor License Agreement and recognized cost of goods sold of $0.1 million related to the corresponding payment to its CVR Holders under the CVR Agreement.” ““Furthermore, we executed a global development license for our legacy combination antiviral assets.””
“In the third quarter of 2026, the Company received and recognized $0.1 million in licensing revenue for its first payment under the PRIDCor License Agreement and recognized cost of goods sold of $0.1…”
“ Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 pat…”
““Furthermore, we executed a global development license for our legacy combination antiviral assets.””
Complete the Halneuron Phase 2b CINP trial and use its topline results to finalize a pivotal Phase 3 program design.
Over the trailing year it converted 0.64x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.